DA-1726
DA-1726 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jun 5, 2026: “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results”.
1 paper studies it3 findingsUpdated
“In the 48 mg cohort, mean body weight reductions from baseline were 6.1% at Day 26 and 9.1% at Day 54 (p<0.05 vs PBO at Day 26)”
- 1 lab
- Human trial1
What did studies of DA-1726 find?
3Studies of DA-1726 measured 3 outcomes; the most studied are body mass index (1 study), waist circumference (1) and body weight (1).
Body mass index
downin humans1
1 study
Body mass index
downin humans1
DA-1726 decreases body mass index in humans (−2.3 kg/m2 at Day 26; −3.4 kg/m2 at Day 54).
“and BMI (−2.3 kg/m2 at Day 26; −3.4 kg/m2 at Day 54; p<0.05 vs PBO at Day 26).”
Human trialobese but otherwise healthy adults48 mgDay 26n = 9
ADA Scientific Sessions 2026 abstract
Waist circumference
downin humans1
1 study
Waist circumference
downin humans1
DA-1726 decreases waist circumference in humans (−5.8 cm at Day 22; −9.8 cm at Day 54).
“Significant reductions were also observed in waist circumference (−5.8 cm at Day 22; −9.8 cm at Day 54; p<0.05 vs PBO)”
Human trialobese but otherwise healthy adults48 mgDay 22n = 9
ADA Scientific Sessions 2026 abstract
Body weight
downin humans1
1 study
Body weight
downin humans1
DA-1726 decreases body weight in humans (-6.1% at Day 26, -9.1% at Day 54).
“In the 48 mg cohort, mean body weight reductions from baseline were 6.1% at Day 26 and 9.1% at Day 54 (p<0.05 vs PBO at Day 26)”
Human trialobese but otherwise healthy adults48 mgDay 26n = 9
ADA Scientific Sessions 2026 abstract